X4 Pharmaceuticals (NASDAQ:XFOR) Announces Quarterly Earnings Results

X4 Pharmaceuticals (NASDAQ:XFOR) released its quarterly earnings results on Tuesday. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03), Zacks reports. The business had revenue of $1.43 million for the quarter, compared to the consensus estimate of $1.07 million.

X4 Pharmaceuticals Price Performance

NASDAQ XFOR opened at $0.26 on Wednesday. The company has a 50 day simple moving average of $0.45 and a 200-day simple moving average of $0.53. X4 Pharmaceuticals has a 52-week low of $0.24 and a 52-week high of $1.60. The firm has a market capitalization of $45.05 million, a price-to-earnings ratio of -2.88 and a beta of 0.39. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80.

Insider Buying and Selling at X4 Pharmaceuticals

In related news, CEO Paula Ragan sold 76,473 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the transaction, the chief executive officer now directly owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. This trade represents a 6.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. Insiders sold 202,663 shares of company stock valued at $91,198 in the last quarter. Company insiders own 1.62% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

An institutional investor recently raised its position in X4 Pharmaceuticals stock. Bank of America Corp DE boosted its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 20.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 133,502 shares of the company’s stock after purchasing an additional 22,485 shares during the quarter. Bank of America Corp DE owned 0.08% of X4 Pharmaceuticals worth $98,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a report on Friday, February 7th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.